Foxx-Orenstein A, Camilleri M, Stephens D, Burton D
Clinical Enteric Neuroscience Translational and Epidemiological Research Program, Mayo Clinic, Rochester, MN 55905, USA.
Gut. 2003 Nov;52(11):1555-61. doi: 10.1136/gut.52.11.1555.
Pharmacological approaches to alter satiation may have an impact on functional upper gastrointestinal disorders and potentially change food intake in obesity.
Our aim was to compare the effects of two doses of octreotide and placebo on postprandial symptoms, gastric accommodation, and gastric emptying using validated non-invasive techniques.
In a randomised, parallel group, two dose, double blind, placebo controlled study, 39 healthy participants (13 per group) were randomised to 30 or 100 micro g octreotide or placebo, administered subcutaneously, 30 minutes before each study. Studies were performed on three separate days and included scintigraphic gastric emptying of solids and liquids, (99m)Tc SPECT imaging to measure fasting stomach volume and gastric accommodation following a 300 ml Ensure meal, and a standardised nutrient drink test to measure maximum tolerated volume and postprandial symptoms.
Relative to placebo, both doses of octreotide delayed gastric emptying of solids (not liquids), increased fasting gastric volume, reduced the change in gastric volume post meal, and decreased the sensation of fullness after a satiating meal.
The somatostatin analogue octreotide significantly alters human gastric functions, including inhibition of the normal reflex responses of gastric volume increase and emptying of the meal. These pharmacological effects suggest studies of the medication in disorders of satiation, including obesity and dyspepsia, are warranted.
改变饱腹感的药理学方法可能会对功能性上消化道疾病产生影响，并有可能改变肥胖患者的食物摄入量。
我们的目的是使用经过验证的非侵入性技术，比较两种剂量的奥曲肽和安慰剂对餐后症状、胃容纳功能和胃排空的影响。
在一项随机、平行组、双剂量、双盲、安慰剂对照研究中，39名健康参与者（每组13人）被随机分为皮下注射30或100μg奥曲肽或安慰剂组，在每次研究前30分钟给药。研究在三个不同的日子进行，包括固体和液体的闪烁扫描胃排空、用（99m）Tc SPECT成像测量空腹胃容积以及在摄入300ml安素餐之后的胃容纳功能，以及一项标准化营养饮料测试以测量最大耐受量和餐后症状。
相对于安慰剂，两种剂量的奥曲肽均延迟了固体（而非液体）的胃排空，增加了空腹胃容积，减少了餐后胃容积的变化，并降低了饱腹感餐后的饱腹感。
生长抑素类似物奥曲肽显著改变人体胃功能，包括抑制胃容积增加和食物排空的正常反射反应。这些药理学效应表明，有必要对该药物在包括肥胖和消化不良在内的饱腹感障碍中的应用进行研究。
